Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Successful pipeline execution in oncology and sustained dominance in virology drive top-line re-acceleration, offsetting upcoming patent cliffs and driving multiple expansion.
Biktarvy LOE Collapse: Rapid market share loss following the loss of exclusivity for Biktarvy without adequate replacement from the oncology pipeline.
Gilead Sciences is a highly cash-generative, mature biopharma business anchored by its dominant HIV franchise. While top-line growth is constrained by patent maturities and competition, immense free cash flow generation easily supports a robust dividend and strategic oncology acquisitions.
Gilead Sciences is a highly cash-generative, mature biopharma business anchored by its dominant HIV franchise. While top-line growth is constrained by patent maturities and competition, immense free cash flow generation easily supports a robust dividend and strategic oncology acquisitions.
Intangible Assets (Patents)
Scale
Accelerated approval of novel oncology therapies.
Hold. The current valuation correctly prices in both the reliable cash generation and the impending virology patent cliffs.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
A stress test scenario combining significant margin compression and revenue stagnation yields a fair value floor around $92-$102, anchored by sustainable dividend yields but penalizing the lack of top-line growth.
Intangible Assets (Patents)
Scale
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $11.6B after capex $559.4M, with terminal value at 72.0% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
Successful pipeline execution in oncology and sustained dominance in virology drive top-line re-acceleration, offsetting upcoming patent cliffs and driving .
If oncology assets show strong commercial uptake, multiple expansion is possible. If not, valuation will compress toward the dividend yield floor.
If oncology assets show strong commercial uptake, multiple expansion is possible. If not, valuation will compress toward the dividend yield floor.
If oncology assets show strong commercial uptake, multiple expansion is possible. If not, valuation will compress toward the floor.
Heavy reinvestment required to replace aging blockbusters.
Accelerated approval of novel oncology therapies.
Heightened regulatory scrutiny on drug pricing.
Heavy reinvestment required to replace aging blockbusters.
Market weight, utilizing the stock for stable yield.
Trim position on excessive multiple expansion above $150 if not supported by pipeline breakthroughs.
Hold. Upside is limited without significant pipeline success, but downside is protected by a strong fundamental yield.
Gilead offers a reliable dividend supported by massive free cash flow, but faces binary risks regarding its ability to replace aging blockbuster drugs with oncology assets.
Hold. Upside is limited without significant pipeline success, but downside is protected by a strong fundamental yield.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Unexpected regulatory pricing pressures in the core HIV portfolio and clinical trial setbacks in oncology lead to revenue stagnation and margin compression.
Rapid market share loss following the loss of exclusivity for Biktarvy without adequate replacement from the oncology pipeline.
Late-stage clinical trial failures for key oncology assets fail to offset the impending revenue decay in virology.
Severe regulatory pricing pressures in the core HIV portfolio significantly compress operating margins.
The five developments that would weaken our investment case.
Market saturation and generic erosion in virology therapies would eliminate top-line gains, weakening baseline cash flows and highlighting dependency on aging pharmaceutical franchises.
Current:2.4% for the period ended 2025-12-31
Alert if< 0.0% over any trailing twelve-month period
Oncology clinical trial failures or asset impairments destroy invested capital, preventing pipeline diversification and leaving the business vulnerable to future virology patent expirations.
Current:2.9% as of the report's 2026-05-08 analysis date
Alert if< 1.5% over any rolling twelve-month period
Higher clinical research spending combined with promotional SG&A inflation would erode operating profitability, diminishing cash generation necessary for sustained dividend growth.
Current:39.7% for the period ended 2025-12-31
Alert if< 34.0% over two consecutive fiscal quarters
Intensifying rival drug launches in long-acting regimens force aggressive discounting and higher commercial rebates, squeezing product gross margins across core treatment categories.
Current:78.8% for the period ended 2025-12-31
Alert if< 74.0% over any fiscal year
Suboptimal capital allocation and unaccretive corporate transactions reduce cash conversion rates, limiting balance sheet flexibility and dampening total investment return profiles.
Current:1.177 as of the report's 2026-05-08 analysis date
Alert if< 1.000 over any trailing twelve-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Solve for the growth rate that makes the model value equal the report-date share price.
The company relies heavily on its mature, cash-generating virology franchise to support strategic acquisitions while managing moderate top-line decay.
If oncology assets show strong commercial uptake, multiple expansion is possible. If not, valuation will compress toward the dividend yield floor.
Warning level: < 0.0% over any trailing twelve-month period. Market saturation and generic erosion in virology therapies would eliminate top-line gains, weakening baseline cash flows and highlighting dependency on aging pharmaceutical franchises.
Warning level: < 1.5% over any rolling twelve-month period. Oncology clinical trial failures or asset impairments destroy invested capital, preventing pipeline diversification and leaving the business vulnerable to future virology patent expirations.
Warning level: < 34.0% over two consecutive fiscal quarters. Higher clinical research spending combined with promotional SG&A inflation would erode operating profitability, diminishing cash generation necessary for sustained dividend growth.
Warning level: < 74.0% over any fiscal year. Intensifying rival drug launches in long-acting regimens force aggressive discounting and higher commercial rebates, squeezing product gross margins across core treatment categories.
Warning level: < 1.000 over any trailing twelve-month period. Suboptimal capital allocation and unaccretive corporate transactions reduce cash conversion rates, limiting balance sheet flexibility and dampening total investment return profiles.
| $27.31B |
| $27.28B |
| $27.12B |
| $28.75B |
| $29.44B |
| +1.9% |
| Gross profit | $20.70B | $21.62B | $20.62B | $22.50B | $23.21B | +2.9% |
| Operating income | $9.28B | $6.75B | $7.80B | $1.67B | $10.82B | +3.9% |
| Net income | $6.23B | $4.59B | $5.67B | $480.0M | $8.51B | +8.1% |
| EPS (diluted) | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 | +8.3% |
| EBITDA | $11.33B | $8.85B | $10.50B | $4.43B | $13.58B | +4.6% |
| R&D | $4.60B | $4.98B | $5.72B | $5.91B | $5.80B | +6.0% |
| SG&A | $5.25B | $5.67B | $6.06B | $6.00B | $5.71B | +2.1% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 29,442,000,000 |
|---|---|
| Cost of revenue | 6,234,000,000 |
| Gross profit | 23,208,000,000 |
| Operating expenses | 11,507,000,000 |
| Operating income | 11,701,000,000 |
| Non-operating items and tax | -3,191,000,000 |
| Net income | 8,510,000,000 |
| Total assets | 59,023,000,000 |
|---|---|
| Cash | 7,564,000,000 |
| Current assets | 18,342,000,000 |
| Total liabilities | 36,405,000,000 |
| Current liabilities | 11,813,000,000 |
| Shareholders’ equity | 22,702,000,000 |
Point-in-time financial data used in the 2026-05-08 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | 27.3B | 11.3B | 6.2B | 11.4B | 10.8B | 579M | 2.1B | 635M | 546M | 3.6B | -4.8B | — | — | — | — | 5.3B | 26.7B | 39.8% | — | 2.8% | — |
| 2022-12-31 | 27.3B | 8.9B | 4.6B | 9.1B | 8.3B | 728M | 2.1B | 637M | 1.4B | 3.7B | -1.5B | — | — | — | — | 5.4B | 25.2B | 40.2% | — | 5.3% | — |
| 2023-12-31 | 27.1B | 10.5B | 5.7B | 8B | 7.4B | 585M | 2.7B | 766M | 1B | 3.8B | -270M | — | — | — | — | 6.1B | 25B | 32.6% | — | 5.1% | — |
| 2024-12-31 | 28.8B | 4.4B | 480M | 10.8B | 10.3B | 523M | 2.8B | 835M | 1.2B | 3.9B | 1.5B | — | — | — | — | 10B | 26.7B | 36.9% | — | 5.5% | — |
| 2025-12-31 | 29.4B | 13.6B | 8.5B | 10B | 9.5B | 563M | 2.8B | 894M | 1.9B | 4B | -1.8B | — | — | — | — | 7.6B | 24.9B | 39.7% | — | 6.0% | — |
GILD trades at 13.9x forward earnings against a peer median of 14.0x; EV/EBITDA of 12.5x against a peer median of 14.1x; 6 peers.
| Accumulate below $120 to provide a margin of safety against patent risks. |
| Johnson & Johnson |
| 17.5x |
| 5.6x |
| 16.6x |
| 26.4% |
| 27.4% |
| ABBV | AbbVie Inc. | 12.5x | 5.7x | 14.1x | 62.2% | 31.6% |
| MRK | Merck & Co. Inc. | 11.8x | 4.2x | 10.9x | 18.9% | 38.6% |
| AMGN | Amgen Inc. | 14.0x | 4.8x | 13.2x | 101.3% | 33.8% |
